Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results from a Prospective Registry in Singapore

Clinical Genitourinary Cancer

Volumn 13, Issue 4, 2015, Pages e285-e295

  Tan, Hui Shan ^a   Li, Huihua ^b   Hong, Yu Wen ^a,c   Toh, Chee Keong ^a   Wong, Alvin ^d   Lopes, Gilberto ^e   Tay, Miah Hiang ^f   Chan, Alexandre ^a,c   Yao, Xin ^g   Tang, Tiffany ^a   Ng, Quan Sing ^a   Kanesvaran, Ravindran ^a   Chau, Noan Minh ^a   Tan, Min Han ^a,h  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e Johns Hopkins Singapore   (Singapore)

^f GLENEAGLES HOSPITAL   (Singapore)

^g TIANJIN MEDICAL UNIVERSITY   (China)

^h INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Dose modification; Kidney cancer; Pharmacokinetics; Real world outcomes; Targeted therapy

Indexed keywords

BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANEMIA; ARTICLE; ASIAN; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTHYROIDISM; KIDNEY METASTASIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SINGAPORE; THROMBOCYTOPENIA; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PYRROLES; SINGAPORE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936985400     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.11.004     Document Type: Article

References (28)

1. J. Norum, C. Nieder, and M. Kondo Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations J Chemother 22 2010 75 82
2. R. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
3. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
4. R.J. Motzer, T.E. Hutson, and D. Cella Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
5. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
6. S. Faivre, C. Delbaldo, and K. Vera Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 2006 25 35
7. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
8. M.E. Gore, C. Szczylik, and C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
9. D.B. La Vine, T.A. Coleman, and C.H. Davis Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma Am J Clin Oncol 33 2010 217 220
10. H. Uemura, N. Shinohara, and T. Yuasa A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety Jpn J Clin Oncol 40 2010 194 202
11. Y. Tomita, N. Shinohara, and T. Yuasa Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma Jpn J Clin Oncol 40 2010 1166 1172
12. C. Yoo, J.E. Kim, and J.L. Lee The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction Jpn J Clin Oncol 40 2010 980 985
13. M.H. Hong, H.S. Kim, and C. Kim Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea Cancer Res Treat 41 2009 67 72
14. H.S. Kim, M.H. Hong, and K. Kim Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles Oncology 80 2011 395 405
15. S.H. Lee, Y.J. Bang, and P. Mainwaring Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy Asia Pac J Clin Oncol 10 2014 237 245
16. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
17. C.H. Barrios, D. Hernandez-Barajas, and M.P. Brown Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma Cancer 118 2012 1252 1259
18. R.J. Motzer, T.E. Hutson, and M.R. Olsen Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 2012 1371 1377
19. C.H. Barrios, D. Hernandez-Barajas, and M.P. Brown Clinical outcome of Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC) with continuous once-daily dosing of sunitinib as first-line therapy (Abstract) Ann Oncol 21 suppl 8 2010 913P
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
22. R. Fisher, A. Pender, and K. Thillai Observation as a treatment strategy for advanced renal cell carcinoma - a call for prospective validation Front Oncol 2 2012 155
23. R. Ihaka, and R. Gentleman R: a language for data analysis and graphics J Comput Graph Stat 5 1996 299 314
24. Y.L. Teo, X.J. Chong, and X.P. Chue Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation Cancer Chemother Pharmacol 73 2014 381 388
25. G. Fernandez, E.S. Spatz, C. Jablecki, and P.S. Phillips Statin myopathy: a common dilemma not reflected in clinical trials Cleve Clin J Med 78 2011 393 403
26. B.I. Rini Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions Clin Cancer Res 13 2007 1098 1106
27. M.R. Harrison, B.R. Hirsch, and D.J. George Real-world outcomes in metastatic renal cell carcinoma: insights from a joint community-academic registry J Oncol Pract 10 2013 e63 e72
28. B.E. Houk, C.L. Bello, D. Kang, and M. Amantea A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients Clin Cancer Res 15 2009 2497 2506